Emerging strategies for lowering serum phosphorous in patients with end-stage renal disease

Bibliography

• CENTERS FOR DISEASE CONTROL AND PREVENTION: State-specific trends in chronic kidney failure – United States, 1990 – 2001. MMWR Morb. Mortal. Wkly Rep. (2004) 53:918-920.
   PubMedGoogle Scholar
• BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium x phosphorous product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. (1998) 31:607-617.
   PubMed Web of Science ®Google Scholar
• OWEN WF, LOWRIE EG: C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. (1998) 54:607-617.
   Google Scholar
• GANESH SK, STACK AG, LEVIN NW, HULBERT-SHEARON T, PORT FK: Association of elevated serum POr, CA x POr product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. (2001) 12:2131-2138.
   PubMed Web of Science ®Google Scholar
• BLOCK GA, KLASSEN PS, LAZARUS JM, OFSTHUN N, LOWRIE EG, CHERTOW GM: Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. (2004) 15:2208-2218.
   PubMed Web of Science ®Google Scholar
• BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. (1998) 31(4):607-617.
   PubMed Web of Science ®Google Scholar
• LOWRIE EG, LEW NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis. (1990) 15(5):458-482.
   PubMed Web of Science ®Google Scholar
• WILLETT WC, BUZZARD M: Nature of Variation in Diet in Nutritional Epidemiology, 2nd Edn. Willett WC (ed) Oxford University Press, New York (1998):33-49.
   Google Scholar
• MARKOWITZ GS, STOKES MB, RADHAKRISHNAN J, D’AGATI VD: Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J. Am. Soc. Nephrol. (2005) 16(11):3389-3396.
   PubMed Web of Science ®Google Scholar
• MARRIOTT WM, HOWLAND J: Phosphate retention as a factor in the production of acidosis in nephritis. Arch. Intern. Med. (1916) 18:708.
   Google Scholar
• BRICKER NS, SLATOPOLSKY E, REISS E, AVIOLI LV: Calcium, phosphorous, and bone in renal disease and transplantation. Arch. Intern. Med. (1969) 123:543-553.
   PubMedGoogle Scholar
• BRICKER NS: On the pathogenesis of the uremic state. An exposition of the ‘trade-off hypothesis.’. N. Engl. J. Med. (1972) 286:1093-1099.
   PubMed Web of Science ®Google Scholar
• MALLUCHE HH, RITZ E et al.: Bone histology in incipient and advanced renal failure. Kidney Int. (1976) 9:355-362.
   PubMed Web of Science ®Google Scholar
• BROWN EM: Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro. Curr. Opin. Nephrol. Hypertens. (1993) 2:541-551.
   PubMedGoogle Scholar
• SARNAK MJ, LEVEY AMJ, LEVEY LS: Epidemiology of cardiac disease in dialysis patients. Semin Dial (1999) 12:69-76.
   Web of Science ®Google Scholar
• FOLEY RN, PARFREY PS, SARNAK MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. (1998) 32(Suppl. 3): S112-S119.
   PubMed Web of Science ®Google Scholar
• MARCHAIS SJ, METIVIER F, GUERIN AP, LONDON GM: Association of hyperphosphatemia with hemodynamic disturbances in end-stage renal disease. Nephrol. Dial. Transplant. (1999) 14:2178-2183.
   PubMed Web of Science ®Google Scholar
• LONDON GM, MARCHAIS SJ, GUERIN AP et al.: Arterial structure and function in end-stage renal disease. Nephrol. Dial. Transplant. (2002) 17:1713-1724.
   PubMed Web of Science ®Google Scholar
• WONG ND, VO A, ABRAHAMSON D et al.: Detection of coronary artery calcium by ultrafast computed tomography and its relation to clinical evidence of coronary artery disease. Am. J. Cardiol. (1994) 73:223-227.
   PubMedGoogle Scholar
• WEXLER L, BRUNDAGE B, CROUSE J et al.: Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association Writing Group. Circulation (1996) 94:1175-1192.
   PubMed Web of Science ®Google Scholar
• JONO S, MCKEE MD, MURRY CE et al.: Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. (2000) 87:e10-e17.
   PubMed Web of Science ®Google Scholar
• GIACHELLI CM, JONO S, SHIOI A et al.: Vascular calcification and inorganic phosphate. Am. J. Kidney Dis. (2001) 38(Suppl. 1):S34-S37.
   PubMed Web of Science ®Google Scholar
• LONDON GM, PANNER B, MARCHAIS SJ, GUERIN AP: Calcification of the aortic valve in dialyzed patients. J. Am. Soc. Nephrol. (2000) 11:778-783.
   PubMed Web of Science ®Google Scholar
• RUFINO M, GARCIA S, JIMENEZ A et al.: Heart valve calcification and calcium X phosphorus product in hemodialysis patients: analysis of optimum values for its prevention. Kidney Int. (2003) 63(Suppl. 85):S115-S118.
   Google Scholar
• WANG AYM, WANG M, WOO J et al.: Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J. Am. Soc. Nephrol. (2003) 13:159-168.
   Google Scholar
• FINE A, ZACHARIAS J: Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. (2002) 61:2210-2217.
   PubMed Web of Science ®Google Scholar
• MAWAD HW, SAWAYA BP, SARIN R et al.: Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin. Nephrol. (1999) 52:160-161.
   PubMed Web of Science ®Google Scholar
• MAZHAR AR, JOHNSON RJ, GILLEN D et al.: Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. (2001) 60:324-332.
   PubMed Web of Science ®Google Scholar
• AHMAD A, O’NEAL KD, HOOD AF et al.: Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am. J. Kidney Dis. (2001) 37:1267-1276.
   Google Scholar
• BLEYER AJ, CHOI M, IGWEMEZIE B et al.: A case control study of proximal calciphylaxis. Am. J. Kidney Dis. (1998) 32:376-383.
   PubMed Web of Science ®Google Scholar
• MOE SM: Calcific uremic arteriolopathy: a new look at an old disorder. Neph SAP (2004) 3:77-83.
   Google Scholar
• HRUSKA KA, TEITELBAUM SL: Mechanisms of disease: renal osteodystrophy. N. Engl. J. Med. (1995) 333:166-175.
   PubMed Web of Science ®Google Scholar
• LOPEZ-HILKER D, DUSSO AS, RAPP NS et al.: Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am. J. Physiol. (1990) 259:F432-F437.
   PubMed Web of Science ®Google Scholar
• LUCAS PA, BROWN RC, WOODHEAD JS, COLES G: 1,25 dihydroxycholecalciferol and parathyroid hormone in advanced renal failure: effects of simultaneous protein and phosphorus restriction. Clin. Nephrol. (1986) 25:7-19.
   PubMedGoogle Scholar
• LUMLERTGUL D, BURKE TJ, GILLUM DM et al.: Phosphate depletion arrests progression of chronic renal failure independent of protein intake. Kidney Int. (1986) 29:658-666.
   PubMedGoogle Scholar
• HAUT LL, ALFREY AC, GUGGENHEIM S, BUDDINGTON B, SCHRIER N: Renal toxicity of phosphate in rats. Kidney Int. (1980) 17:722-731.
   PubMed Web of Science ®Google Scholar
• PASTAN S, BAILEY J: Dialysis therapy. N. Engl. J. Med. (1998) 338:1428-1437.
   PubMed Web of Science ®Google Scholar
• KOPPLE JD: National Kidney Foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am. J. Kidney Dis. (2001) 37(Suppl. 2):S66-S70.
   PubMed Web of Science ®Google Scholar
• EKNOYAN G, LEVIN A, LEVIN NW, NATIONAL KIDNEY FOUNDATION: Bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. (2003) 42(Suppl. 3):S1-S201.
   PubMed Web of Science ®Google Scholar
• GOTCH FA, PANLILIO F, SERGEYEVA O et al.: A kinetic model of inorganic phosphorus mass balance in hemodialysis therapy. Blood Purif. (2003) 21:51-57.
   PubMed Web of Science ®Google Scholar
• ZEHNDER C, GUTWILLER JP, RENGGLI K: Hemodiafiltration – a new treatment option for hyperphosphatemia in hemodialysis patients. Clinical Nephrol. (1999) 52:152-159.
   Google Scholar
• DELMEZ JA, SLATOPOLSKY E, MARTIN KJ, GEARING BN, HARTER HR: Minerals, vitamin D and parathyroid hormone in continuous ambulatory peritoneal dialysis. Kidney Int. (1982) 21:862-867.
   PubMed Web of Science ®Google Scholar
• HSU CH: Are we mismanaging calcium and phosphate metabolism in renal failure? Am. J. Kidney Dis. (1997) 29:641-649.
   PubMed Web of Science ®Google Scholar
• MALLICK NP, GOKAL R: Haemodialysis. Lancet (1999) 353:737-742.
   PubMedGoogle Scholar
• LINDSAY RM, HEIDENHEIM P, LEITCH R et al. THE DAILY/NOCTURNAL DIALYSIS STUDY GROUP: Short daily versus long nocturnal hemodialysis. ASAIO (2001) 47:449-455.
   Google Scholar
• MUCSI I, HERCZ G, ULDALL R, OUWENDYK M, FRANCOEUR R, PIERRATOS A: Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int. (1998) 53:1399-1404.
   PubMed Web of Science ®Google Scholar
• AL-HEJAILI F, KORTAS C, LEITCH R et al.: Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J. Am. Soc. Nephrol. (2003) 14:2322-2328.
   PubMedGoogle Scholar
• SHEIKH MS, MAGUIRE JA, EMMETT M et al.: Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro and in vivo study. J. Clin. Invest. (1989) 83:66-73.
   PubMed Web of Science ®Google Scholar
• RAMIREZ JA, EMMETT M, WHITE MG et al.: The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int. (1986) 30:753-759.
   PubMed Web of Science ®Google Scholar
• CLARKSON EM, LUCK VA, HYNSON WV et al.: The effect of aluminum hydroxide on calcium, phosphorus and aluminum balances, the serum parathyroid hormone concentrations and the aluminum content of bone in patients with chronic renal failure. Clin. Sci. (1972) 43:519-531.
   PubMed Web of Science ®Google Scholar
• BERLYNE GM, BEN-ARI J, PEST D et al.: Hyperaluminaemia from aluminum resins in renal failure. Lancet (1970) 2:494-496.
   PubMed Web of Science ®Google Scholar
• CLARKSON EM, LUCK VA, HYNSON WV et al.: The effect of aluminium hydroxide on calcium, phosphorus and aluminium balances, the serum parathyroid hormone concentration and the aluminium content of bone in patients with chronic renal failure. Clin. Sci. (1972) 43:519-531.
   PubMed Web of Science ®Google Scholar
• ALFREY AC, MISHELL JM, BURKS J et al.: Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis. Trans. Am. Soc. Artif. Intern. Organs (1972) 18:257-261.
   PubMedGoogle Scholar
• ALFREY AC, LEGENDRE GR, KAEHNY WD: The dialysis encephalopathy syndrome: possible aluminum intoxication. N. Engl. J. Med. (1976) 294:184-188.
   PubMed Web of Science ®Google Scholar
• PIERIDES AM, EDWARDS WG, CULLUM UX, MCCALL JT, ELLIS HA: Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. Kidney Int. (1980) 8:115-124.
   Google Scholar
• MAKOFF DL, GORDON A, FRANKLIN SS, GERSTEIN AR, MAXWELL MH: Chronic calcium carbonate therapy in uremia. Arch. Intern. Med. (1969) 123:15-21.
   PubMed Web of Science ®Google Scholar
• RITZ E: Managing mineral balance in end-stage renal disease. Nephrol. Dial. Transplant. (2004) 19(Suppl. 1):S1-S3.
   PubMedGoogle Scholar
• INDRIDASON OS, QUARLES LD, FOR THE DURHAM RENAL OSTEODYSTROPHY STUDY GROUP: Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int. (2000) 57:282-292.
   PubMed Web of Science ®Google Scholar
• SLATOPOLSKY E, WEERTS C, LOPEZ-HILKER S et al.: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N. Engl. J. Med. (1986) 315:157-161.
   PubMed Web of Science ®Google Scholar
• SLATOPOLSKY E, WEERTS C, NORWOOD K et al.: Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int. (1989) 36:897-903.
   PubMed Web of Science ®Google Scholar
• CLARKSON EM, EASTWOOD JB, KOUTSAIMANIS KG, DEWARDENER HE: Net intestinal absorption of calcium in patients with chronic renal failure. Kidney Int. (1973) 3:258-263.
   Google Scholar
• HARDY P, SECHET A, HOTTELART C et al.: Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif. Organs (1998) 22:569-5733.
   PubMed Web of Science ®Google Scholar
• TAN CC, HARDEN PN, RODGERS RS: Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate. Nephrol. Dial. Transplant. (1996) 11:851-853.
   PubMed Web of Science ®Google Scholar
• MAI ML, EMMETT M, SHEIKH MS et al.: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. (1989) 36:690-695.
   PubMed Web of Science ®Google Scholar
• EMMETT M, SIRMON MD, KIRKPATRICK WG et al.: Calcium acetate control of serum phosphorus in hemodialysis patients. Am. J. Kidney Dis. (1991) 17:544-550.
   PubMed Web of Science ®Google Scholar
• MORINIERE P, DJERAD M, BOUDAILLIEZ B et al.: Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia. Nephron (1992) 60:6-11.
   PubMedGoogle Scholar
• CARAVACA F, SANTOS I, CUBERO JJ et al.: Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron (1992) 60:423-427.
   PubMed Web of Science ®Google Scholar
• SCHAEFER K, SCHEER J, ASMUS G et al.: The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrol. Dial. Transplant. (1991) 6:170-175.
   PubMed Web of Science ®Google Scholar
• NOLAN CR, CALIFANO JR, BUTZIN CA: Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int. (1990) 38:937-941.
   PubMed Web of Science ®Google Scholar
• DELMEZ JA, KELBER J, NORWORD KY et al.: Magnesium carbonate as a phopphate binder: a prospective, controlled, cross over study. Kidney Int. (1996) 49:163-167.
   PubMed Web of Science ®Google Scholar
• DAMMENT SJP, WEBSTER I: The pharmacology of lanthanum carbonate (Fosrenol®): a new non-aluminum-, non-calcium-based phosphate binder [Abstract]. J. Am. Soc. Nephrol. (2003) 14:204A.
   Web of Science ®Google Scholar
• HUTCHISON AJ, SPEAKE M, DEWBERRY K, FOX JS: Lanthanum carbonate: a novel non-calcaemic phosphate binder in dialysis patients [Abstract]. Periton. Dial. Int. (1998) 18:S38.
   Google Scholar
• FINN WF, JOY MS, HLADIK GA, AND THE LANTHANUM STUDY GROUP: Results of a randomized dose-ranging, placebo controlled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis [Abstract]. J. Am. Soc. Nephrol. (1999) 10:261A.
   Google Scholar
• HUTCHISON AJ: Improving phosphate-binder therapy as a way forward. Nephrol. Dial. Transplant. (2004) 19(Suppl. 1):i19-i24.
   PubMedGoogle Scholar
• LACOUR B, LUCAS A, AUCHERE D, RUELLAN N, DE SERRE PATEY NM, DRUEKE TB: Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. (2005) 67:1062-1069.
   PubMed Web of Science ®Google Scholar
• BEHETS GJ, DAMS G, DAMMENT S et al.: Does the phosphate binder lanthanum carbonate affect bone in chronic renal failure rats? J. Am. Soc. Nephrol. (2004) 15:2219-2228.
   PubMed Web of Science ®Google Scholar
• D’HAESE PC, SPASOVSKI GB, SIKOLE A et al.: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. (2003) 63(Suppl. 85):S73-S78.
   Web of Science ®Google Scholar
• MALLUCHE HH, GAUGERE MC, WANG G, DEMMENT SJP, WEBSTER I: No evidence of osteomalacia in dialysis patients treated with lanthanum carbonate up to 5 years [Abstract]. J. Am. Soc. Nephrol. (2004) 15:270A.
   Google Scholar
• BURKE SL, SLATOPOLSKY EA, GOLDBERG DI: Renagel, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol. Dial. Transplant. (1997) 12:1640-1644.
   PubMed Web of Science ®Google Scholar
• CHERTOW GM, BURKE SK, RAGGI P, FOR THE TREAT TO GOAL WORKING GROUP: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. (2002) 62:245-252.
   PubMed Web of Science ®Google Scholar
• CHERTOW GM, BURKE SK, LAZARUS JM et al.: Poly[allylamine hydrochloride] (Renagel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am. J. Kidney Dis. (1997) 29:66-71.
   PubMed Web of Science ®Google Scholar
• SLATOPOLSKY EA, BURKE SK, DILLON MA, THE RENAGEL STUDY GROUP: RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int. (1999) 55:299-307.
   PubMed Web of Science ®Google Scholar
• CHERTOW GM, BURKE SK, RAGGI P, TREAT TO GOAL WORKING GROUP: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. (2002) 62:245-252.
   PubMed Web of Science ®Google Scholar
• MITSOPOULOS E, GRIVEAS I, ZANOS S et al.: Increase in serum magnesium level in haemodialysis patients receiving sevelamer hydrochloride. Int. Urol. Nephrol. (2005) 37(2):321-328.
   Google Scholar
• CASTRO R, HERMAN A, FERREIRA C, TRAVASSOS F, NUNES-AZEVEDO J, OLIVEIRA M: RenaGel efficacy in severe secondary hyperparathyroidism. Nefrologia (2002) 22:448-455.
   Google Scholar
• BROWN EM, GAMBA G, RICCARDI D et al.: Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature (1993) 366:575-580.
   PubMed Web of Science ®Google Scholar
• BLOCK G, MARTIN KJ: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. New Engl. J. Med. (2004) 350:1516-1525.
   PubMed Web of Science ®Google Scholar